These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 37371463)
1. Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma. Huang X; Tan J; Chen M; Zheng W; Zou S; Ye X; Li Y; Wu M Biomolecules; 2023 May; 13(6):. PubMed ID: 37371463 [TBL] [Abstract][Full Text] [Related]
2. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma. Huang S; Sun L; Hou P; Liu K; Wu J Front Immunol; 2022; 13():944898. PubMed ID: 36148220 [TBL] [Abstract][Full Text] [Related]
3. Loss of MTA2-mediated downregulation of PTK7 inhibits hepatocellular carcinoma metastasis progression by modulating the FAK-MMP7 axis. Hu HM; Lee HL; Liu CJ; Hsieh YH; Chen YS; Hsueh KC Environ Toxicol; 2024 Apr; 39(4):1897-1908. PubMed ID: 38050825 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma. Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL Front Immunol; 2021; 12():781087. PubMed ID: 35069553 [TBL] [Abstract][Full Text] [Related]
5. MTA2 promotes HCC progression through repressing FRMD6, a key upstream component of hippo signaling pathway. Guan C; Chang Z; Gu X; Liu R Biochem Biophys Res Commun; 2019 Jul; 515(1):112-118. PubMed ID: 31128910 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of metastasis-associated protein 2 is associated with hepatocellular carcinoma size and differentiation. Lee H; Ryu SH; Hong SS; Seo DD; Min HJ; Jang MK; Kwon HJ; Yu E; Chung YH; Kim KW J Gastroenterol Hepatol; 2009 Aug; 24(8):1445-50. PubMed ID: 19702911 [TBL] [Abstract][Full Text] [Related]
7. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma. Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633 [TBL] [Abstract][Full Text] [Related]
8. Expression of MTA2 and Ki-67 in hepatocellular carcinoma and their correlation with prognosis. Shi W; Hu J; Zhu S; Shen X; Zhang X; Yang C; Gao H; Zhang H Int J Clin Exp Pathol; 2015; 8(10):13083-9. PubMed ID: 26722504 [TBL] [Abstract][Full Text] [Related]
9. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma. Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y Front Immunol; 2022; 13():994019. PubMed ID: 36177006 [TBL] [Abstract][Full Text] [Related]
10. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker. Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W Front Immunol; 2021; 12():646523. PubMed ID: 33679809 [TBL] [Abstract][Full Text] [Related]
11. Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients. Wang S; Wu X; Wu X; Cheng J; Chen Q; Qi Z BMC Cancer; 2024 Jan; 24(1):156. PubMed ID: 38291366 [TBL] [Abstract][Full Text] [Related]
12. SMYD3 associates with the NuRD (MTA1/2) complex to regulate transcription and promote proliferation and invasiveness in hepatocellular carcinoma cells. Yang Y; Qiu R; Zhao S; Shen L; Tang B; Weng Q; Xu Z; Zheng L; Chen W; Shu G; Wang Y; Zhao Z; Chen M; Ji J BMC Biol; 2022 Dec; 20(1):294. PubMed ID: 36575438 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity. Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695 [TBL] [Abstract][Full Text] [Related]
14. MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity. Si W; Liu X; Wei R; Zhang Y; Zhao Y; Cui L; Hong T Cell Death Dis; 2019 Feb; 10(3):206. PubMed ID: 30814496 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer. Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148 [TBL] [Abstract][Full Text] [Related]
16. An integrative analysis reveals the prognostic value and potential functions of MTMR2 in hepatocellular carcinoma. Yao Y; Lai J; Yang Y; Wang G; Lv J Sci Rep; 2023 Oct; 13(1):18701. PubMed ID: 37907649 [TBL] [Abstract][Full Text] [Related]
17. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma. Jin W; Wang G; Dong M; Wang X Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503 [TBL] [Abstract][Full Text] [Related]
18. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma. Liu R; Liu Y; Zhang F; Wei J; Wu L Front Immunol; 2023; 14():1146411. PubMed ID: 37063920 [TBL] [Abstract][Full Text] [Related]
19. Comprehensively prognostic and immunological analysis of VRK Serine/Threonine Kinase 1 in pan-cancer and identification in hepatocellular carcinoma. Chen D; Zhou W; Chen J; Wang J Aging (Albany NY); 2023 Dec; 15(24):15504-15524. PubMed ID: 38157278 [TBL] [Abstract][Full Text] [Related]
20. Deep dissection of stemness-related hierarchies in hepatocellular carcinoma. Liang R; Hong W; Zhang Y; Ma D; Li J; Shi Y; Luo Q; Du S; Song G J Transl Med; 2023 Sep; 21(1):631. PubMed ID: 37717019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]